This article first appeared on GuruFocus .
Release Date: September 22, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
PureTech Health PLC ended H1 2026 with $220 million in cash and short-term investments, providing operational runway at least through the end of 2028.
-
Seaport Therapeutics completed a successful IPO on NASDAQ, raising $260 million, validating the hub-and-spoke model and providing external capital.
-
Gallup Oncology received FDA Fast Track designation for LYT200 in relapsed/refractory high-risk MDS, and completed a successful End of Phase 1 meeting, positioning it for Phase 2 and external financing.
-
The innovation engine is running ahead of target, with at least three concept-stage programs per year, and the team expects to unveil new programs in H1 2027.
-
PureTech Health PLC is committed to returning capital to shareholders and maintaining capital discipline, with a significant reduction in operating cash burn expected going forward.
Negative Points
-
PureTech Health PLC's cash position decreased from $277.1 million at year-end 2025 to $220 million at H1 2026, partly due to increased R&D spend.
-
The estimated future proceeds from Cobenfy royalties and milestones have been materially downgraded to approximately $50 million based on analyst consensus, down from previous estimates.
-
Gallup Oncology's Phase 2 STRIDE MDS trial is not expected to be pivotal and will take approximately 30-33 months to complete, with initiation contingent on external financing.
-
Celia Therapeutics, while spun out, will require additional future financing to complete its Phase 3 trial, potentially leading to further dilution or capital needs.
-
PureTech Health PLC has reserved $70 million for future investment in Celia, which reduces the available cash for other opportunities or shareholder returns.
Q & A Highlights
Q: On the planned design of the STRIDE MDS trial, has the FDA required any specific biomarkers, or are you planning to look at any? And on the next wave of programs to be unveiled next year, how should we think about disease areas will you stay within neurology or be disease agnostic? A: Eric Elenko (Acting CEO of Gallup Oncology) said the approach is mutation-agnostic, which reflects where the need is in relapsed/refractory high-risk MDS, where only one approved therapy (Tibsovo) covers about 3% of patients with an IDH1 mutation. In the Phase 1b, a number of different mutations were present, including in responders (KRAS pathway, B-core, PNTP), giving a sampling more representative of a subsequent study. The FDA was fine with a mutation-agnostic approach and did not require biomarker selection, and there are currently no plans for it. Rob Line (CEO) added that on future innovation, PureTech is generally agnostic but has a bias toward areas of prior success. Greg Siegates (VP of Research and Innovation) noted multiple opportunities identified this year fitting the model, with continued focus on small molecule therapeutics and CNS/neuropsychiatry, while remaining somewhat agnostic to indication given the model's broad applicability and blockbuster potential.
Q: On capital allocation, you have resources that dwarf the market cap. How are you thinking about deploying capital going forward, and how are you approaching financing for Gallup? A: Rob Line (CEO) said PureTech is looking at a range of options for Gallup, believing the indication and data open up different possibilities. The framework centers on the relative cost of capital equity, pharma partnership, or other structures each carry different costs such as dilution, capping upside, or upfront cash and the company wants to remain open-minded, targeting completion of financing by the first half of next year to allow a market approach without being rushed. More broadly, he said the focus is maintaining operational runway without holding too much cash, since cash piles don't create value; capital should be put to work or returned to shareholders. Within the portfolio, opportunities range from late-stage (e.g., $70 million reserved for future Selea financing) to early-stage innovation programs, and decisions weigh return, money multiple, and time horizon, alongside considering capital returns to shareholders.
Q: You've flagged that shifting the duprofenidone cost to Selea should contribute significantly to lower OpEx going forward. Can you quantify that, even directionally? A: Rob Line (CEO) confirmed that a key driver for spinning out Selea was externalizing the significant late-stage clinical spend away from PureTech's P&L, which completed just over the half year and is expected to significantly benefit PureTech cash flows in H2 2026. On a clean basis, go-forward cash burn including overhead and crucially innovation spend is expected to be between $30 million and $40 million a year, a significant reduction from the roughly $90 million a year burn when later-stage clinical programs were run internally.
Q: On the STRIDE MDS trial timeline, can you help us understand what that might look like is it similar in format to Tibsovo? And on Selea, now that it's spun out with a smaller controlling holding, are there plans to build out programs and platform like Seaport, or is it a pure-play single asset? A: Eric Elenko (Acting CEO of Gallup Oncology) said the Gallup trial will commence following receipt of external capital, with initial conservative projections of somewhat under three years to complete around 30 to 33 months depending on the number of sites selected and observed recruitment rates. Rob Line (CEO) said Selea currently has a single asset, the IPF asset now in a pivotal registrational Phase 3 trial with line of sight to readout, and while there have been no disclosures about additional assets, the company will consider that as it matures. He noted Selea raised enough cash to year-end but will inevitably need to raise more to complete Phase 3, which may bring opportunities to consider other programs.
Q: On the STRIDE trial design, is this largely the best-case design you could have imagined from your FDA discussions, and does it support the financing/partnership potential? Given the unmet need, if you get a very strong response, is it potentially a pivotal trial, or is that a stretch? A: Eric Elenko (Acting CEO of Gallup Oncology) said the FDA meeting provided very clear direction, with two goals: confirming the efficacy observed in Phase 1b and satisfying the FDA's Project Optimist requirements on dose selection (favoring a biologically meaningful dose over the maximum tolerated dose). He noted the Fast Track designation validates the view that LYT200 is an active drug. Unlike Phase 1b, STRIDE MDS is larger, double-blind, and randomized, allowing clear discernment of LYT200's contribution in combination with HMA. If similar efficacy and the excellent Phase 1b safety profile are confirmed, Gallup would be in a very good position with both commercial and financial optionality and potentially more streamlined next steps. He explicitly stated they are not guiding that this is a pivotal study, though the data would be extremely meaningful.
Q: On the overall development strategy, you talk about three concept-stage programs and may announce a new development candidate in the first half of next year. How many run in parallel, do you have the bandwidth, and what are the decision points for identifying a candidate? A: Rob Line (CEO) said PureTech guides at least three concept-stage programs per year and is currently running ahead of that, with pleasant surprise at both the quantity and quality of opportunities. No details will be shared until next year, but he expects followers of the PureTech story will recognize the hallmarks of the LIFE model and similarities to Karuna/Kovepsi and more recently Seaport and Selea. Greg Siegates (VP of Research and Innovation) described a rigorous process starting with unmet clinical need, identifying validated molecules and mechanisms and their limitations, pressure-testing clinical data with leading clinicians, and advancing programs through predefined preclinical proof-of-concept criteria designed to confirm the underlying limitation has been addressed before forming a development candidate.
Q: You've targeted at least three concept-stage programs progressed per year. How many are currently in the pipeline today, and what would need to be true for one to be named as a new founded entity candidate? A: Rob Line (CEO) said the rigorous process is informed not just by the innovation team but by broader corporate knowledge and history at PureTech, including having taken programs all the way through registration, approval, and dosing to patients.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
